Effects of hTERT on metal ion-induced genomic instability

Oncogene

Volumn 25, Issue 24, 2006, Pages 3424-3435

  Glaviano, A ^a,b   Nayak, V ^a   Cabuy, E ^c   Baird, D M ^d   Yin, Z ^a   Newson, R ^e   Ladon, D ^a   Rubio, M A ^f   Slijepcevic, P ^c   Lyng, F ^b   Mothersill, C ^b   Case, C P ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

^c BRUNEL UNIVERSITY   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Carcinogenesis; Chromium; Genomic instability; hTERT; Vanadium

Indexed keywords

BETA GALACTOSIDASE; CHROMIUM; METAL ION; TELOMERASE REVERSE TRANSCRIPTASE; VANADIUM;

ANEUPLOIDY; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL SURVIVAL; CHROMATID ABERRATION; CHROMOSOME DAMAGE; CLONOGENESIS; CONTROLLED STUDY; DICENTRIC CHROMOSOME; FIBROBLAST; GENOMIC INSTABILITY; GENOTOXICITY; HUMAN; HUMAN CELL; MICRONUCLEUS; PRIORITY JOURNAL; PROGENY; TETRAPLOIDY;

APOPTOSIS; BETA-GALACTOSIDASE; CARCINOGENS; CELL SURVIVAL; CHROMIUM; CHROMOSOME ABERRATIONS; DNA-BINDING PROTEINS; FIBROBLASTS; GENOMIC INSTABILITY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; IONS; MICRONUCLEUS TESTS; TELOMERASE; TIME FACTORS; VANADIUM;

EID: 33745045008     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209399     Document Type: Article

References (76)

1. Andreassen PA, Lohez OD, Margolis RL. (2003). Mutat Res 532: 245-253.
2. Baird DM, Rowson J, Wynford-Thomas D, Kipling D. (2003). Nature Genet 33: 203-207.
3. Bindra RS, Glazer PM. (2005). Mutat Res 569: 75-85.
4. Blackburn EH. (2001). Cell 106: 661-673.
5. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA et al. (1997). Cell 91: 25-34.
6. Cabuy E, Newton C, Roberts T, Newbold R, Slijepcevic P. (2004). Cytometry 62A: 150-161.
7. Chan SW, Blackburn EH. (2003). Mol Cell 11: 1379-1387.
8. Cheng RYS, Zhao A, Alvord WG, Powell DA, Bare RM, Masuda A et al. (2003). Toxicol Appl Pharmacol 191: 22-39.
9. Coen N, Mothersill C, Kadhim M, Wright EG. (2001). J Pathol 195: 293-299.
10. Coen N, Kadhim MA, Wright EG, Case CP, Mothersill CE. (2003). Br J Cancer 88: 548-552.
11. Corinna M, Palanca-Wessels A, Klingelhutz A, Reid BJ, Norwood TH, Opheim KE et al. (2003). Carcinogenesis 24: 1183-1190.
12. Cui W, Aslam S, Fletcher J, Wylie D, Clinton M, Clark AJ. (2002). J Biol Chem 277: 38531-38539.
13. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C et al. (1995). Proc Natl Acad Sci USA 92: 9363-9367.
14. Dutrillaux B, Gerbault-Sereau M, Remvikos Y, Zafrani B, Prieur M. (1991). Breast Cancer Res Treat 19: 245-255.
15. Fenech M. (2000). Mutat Res 455: 81-95.
16. Fenech M, Morley AA. (1985). Mutat Res 148: 29-36.
17. Gorbunova V, Seluanov A, Pereira-Smith OM. (2002). J Biol Chem 41: 38540-38549.
18. Ha L, Ceryak S, Patierno SR. (2004). Carcinogenesis 11: 2265-2274.
19. Hackett JA, Feldser DA, Greider CW. (2001). Cell 106: 275-286.
20. Hardin J, Hilde J. (2001). College Station. Stata Press: TX, USA.
21. Henegariu O, Heerema NA, Lowe Wright L, Bray-Ward P, Ward DC, Vance GH. (2001). Cytometry 43: 101-109; http://www.osha.gov/SLTC/healthguidelines/ vanadiumpentoxidedust/recognition.html#workplacemonitoring.
22. IARC (International Agency for Research on Cancer) (1990). Monograph on the Evaluation of Carcinogenic Risk to Humans, Chromium. Nickel and Welding: Lyon, France.
23. Ivancsits S, Pilger A, Diem E, Schaffer A, Rudiger HW. (2002). Mutat Res 519: 25-35.
24. Jiang XR, Jimenez G, Chang E, Frolkis M, Kusler B, Sage M; et al. (1999). Nat Genet 21: 111-114.
25. Kadhim MA, MacDonald DA, Goodhead SA, Lorimore SA, Marsden SJ, Wright EG. (1992). Nature 355: 738-740.
26. Karlseder J, Hoke K, Mirzoeva OK, Bakkenist C, Kastan MB, Petrini JH et al. (2004). PLoS Biol 2: E240.
27. Karlseder J, Smogorzewska A, de Lange T. (2002). Science 295: 2446-2449.
28. Kerr JFK, Harmon BV. (1991). Definition and incidence of apoptosis. An historical perspective. In: Tomei LD, Cope FO (eds). Apoptosis. The Molecular Basis of Cell Death. Cold Springs Harbour Laboratory: NY, pp 5-9.
29. Kim NW, Wu F. (1997). Nucleic Acids Res 25: 2595-2597.
30. Koizumi S, Yamada H. (2003). J Occup Health 45: 331-334.
31. Lanni JS, Jacks T. (1998). Mol Cell Biol 18: 1055-1064.
32. Little JB. (2003). Oncogene 22: 6978-6987.
33. Luther MJ, Davies E, Muller D, Harrison M, Bone AJ, Persaud SJ et al. (2005). Am J Physiol Endocrinol Metab 288: E502-E509.
34. McClintock B. (1941). Genetics 26: 234-282.
35. McIlrath J, Bouffler SD, Samper E, Cuthbert A, Wojcik A, Szumiel I et al. (2001). Cancer Res 61: 912-915.
36. Mese H, Ueyama Y, Suzuki A, Nakayama S, Sasaki A, Hamakawa H et al. (2001). Chemotherapy 47: 136-142.
37. Morales CP, Holt SE, Ouellette M, Kaur KJ, Yan Y, Wilson KS et al. (1999). Nat Genet 21: 115-118.
38. Mothersill C, Crean M, Lyons M, McSweeney J, Mooney R, O'Reilly J et al. (1998). Int J Rad Biol 74: 673-680.
39. Mothersill C, Seymour C. (2004). Mutat Res 568: 121-128.
40. National Institute for Occupational Safety and Health (NIOSH). (1997). NIOSH Pocket Guide to Chemical Hazards. US Department of Health and Human Services, Public Health Service, Centre for Disease Control and Prevention: Washington, DC.
41. Nicoletti L, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. (1991). J Immun Meth 139: 271-279.
42. Nijjar T, Bassett E, Garbe J, Takenaka Y, Stampfer MR, Gilley D et al. (2005). Oncogene 24: 3369-3376.
43. Noble JR, Zhong ZE, Neumann AA, Melki JR, Clark SJ, Reddel RR. (2004). Oncogene 23: 3116-3121.
44. Obe G, Pfeiffer P, savage JRK, Johannes C, Goedecke W, Jeppesen P et al. (2002). Mutat Res 504: 17-36.
45. O'Brien TJ, Ceryak S, Patierno SR. (2003). Mutat Res 533: 3-36.
46. Park HR, Min SK, Cho HD, Kim KH, Shin HS, Park YE. (2004). J Cutan Pathol 31: 544-549.
47. Piboonniyom S, Duensing S, Swilling NW, Hasskarl J, Hinds PW, Munger K. (2003). Cancer Res 63: 476-483.
48. Pritchard DE, Ceryak S, Ha L, Fornsaglio JL, Hartman SK, O'Brien TJ et al. (2001). Cell Growth Differ 12: 487-496.
49. Puck TT, Marcus PI. (1956). J Exp Med 103: 653-666.
50. Rajagopalan H, Lengauer C. (2004). Nature 432: 338-341.
51. Ramirez P, Eastmond DA, Laclette JP, Ostrosky-Wegman P. (1997). Mutat Res 386: 291-298.
52. Reid BJ, Haggitt RC, Rabinovitch PS. (1987). Gasroenterology 93: 1-11.
53. Risques RA, Moreno V, Ribas M, Marcuello V, Capella G, Peinado M. (2003). Cancer Res 63: 7206-7214.
54. Rubio MA, Kim SH, Campisi J. (2002). J Biol Chem 277: 28609-28617.
55. Rubio MA, Davalos AR, Campisi J. (2004). Exp Cell Res 298: 17-27.
56. Sabatier L, Lebeau J, Dutrillaux B. (1994). Int J Rad Biol 66: 611-613.
57. Sciandrello G, Caradonna F, Mauro M, Barbata G. (2004). Carcinogenesis 25: 413-417.
58. der-Sarkissian H, Bacchetti S, Cazes L, Londono-Vallejo JA. (2004). Oncogene 23: 221-228.
59. Seone AI, Dulout FN. (2001). Mutat Res 490: 99-106.
60. Seymour CB, Mothersill C, Alper T. (1986). Int J Rad Biol 50: 167-169.
61. Seymour CB, Mothersill C, Mooney R, Moriarty M, Tipton KF. (2003). Br J Cancer 89: 1979-1986.
62. Shi Q, King RW. (2005). Nature 437: 1038-1042.
63. Smorgorzewska A, Karlseder J, Holtgreve-Grez H, Jauch A, de Lange T. (2002). Curr Biol 12: 1635-1644.
64. Sorensen M, Schinns RPF, Hertel O, Loft S. (2005). Cancer Epidemiol Biomarkers Prev 14: 1340-1343.
65. van Steensel B, Smogorzewska A, de Lange T. (1998). Cell 92: 401-413.
66. Storchova Z, Pellman D. (2004). Nat Rev Mol Cell Biol 5: 45-54.
67. Sugden KD, Stearns DM. (2000). J Environ Pathol Toxicol Oncol 19: 215-230.
68. Thomas P, Umegaki K, Fenech M. (2003). Mutagenesis 18: 187-194.
69. Tsuneta Y, Ohsaki Y, Kimura K, Mikami H, Abe S, Murao M. (1980). Thorax 35: 294-297.
70. Tsutsui T, Kumakura S, Yamamoto A, Kanai H, Tamura Y, Kato T et al. (2002). Carcinogenesis 23: 2111-2117.
71. Urushibara A, Kodama S, Suzuki K, Desa MBM, Suzuki F, Tsutsui T et al. (2004). Biochem Biophys Res Comm 313: 1037-1043.
72. Uetake Y, Sluder G. (2004). J Cell Biol 165: 609-615.
73. Wong C, Stearns T. (2005). BMC Cell Biol 6: 6.
74. Wood LD, Halvorsen TL, Dhar S, Baur JA, Pandita RK, Wright WE et al. (2001). Oncogene 20: 278-288.
75. World Health Organisation (2001). Vanadium Pentoxide and Other Inorganic Vanadium Compounds. Concise International Chemical Assessment Documents (Document 29).
76. Zhang Y, Cao EH, Qin JF. (2005). Eur J Pharmacol 516: 1-9.